Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases

J Med Chem. 2017 May 11;60(9):3814-3827. doi: 10.1021/acs.jmedchem.7b00018. Epub 2017 Apr 19.

Abstract

The design of selective matrix metalloproteinase (MMP) inhibitors that also possess favorable solubility properties has proved to be especially challenging. A prior approach using collagen-model templates combined with transition state analogs produced a first generation of triple-helical peptide inhibitors (THPIs) that were effective in vitro against discrete members of the MMP family. These THPI constructs were also highly water-soluble. The present study sought improvements in the first generation THPIs by enhancing thermal stability and selectivity. A THPI selective for MMP-2 and MMP-9 was redesigned to incorporate non-native amino acids (Flp and mep), resulting in an increase of 18 °C in thermal stability. This THPI was effective in vivo in a mouse model of multiple sclerosis, reducing clinical severity and weight loss. Two other THPIs were developed to be more selective within the collagenolytic members of the MMP family. One of these THPIs was serendipitously more effective against MMP-8 than MT1-MMP and was utilized successfully in a mouse model of sepsis. The THPI targeting MMP-8 minimized lung damage, increased production of the anti-inflammatory cytokine IL-10, and vastly improved mouse survival.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy
  • Humans
  • Matrix Metalloproteinases / drug effects*
  • Multiple Sclerosis / drug therapy
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Protease Inhibitors / pharmacology*
  • Protease Inhibitors / therapeutic use
  • Sepsis / drug therapy
  • Substrate Specificity

Substances

  • Peptides
  • Protease Inhibitors
  • Matrix Metalloproteinases